Business
Neurochem files shelf prospectus in connection with previously announced equity line of credit facility and convertible notes financings
Neurochem files shelf prospectus in connection with previously announced equity line of credit facility and convertible notes financings.
About this update from Bluenergies Ltd.
[{"type":"text","content":"\n\n\n\nLAVAL, QC, Jan. 17 /CNW Telbec/ - Neurochem Inc. (NASDAQ: NRMX, TSX: NRM)\nannounced today that, in accordance with agreements entered into at the time\nof the establishment, in August 2006, of its equity line of credit facility\nand the issuance, in November 2006, of US$42.085 million aggregate principal\namount of its 6% senior convertible notes due 2026, it has filed a preliminary\nshort form base shelf prospectus with the Canadian securities regulators and a\nregistration statement with the U.S. Securities and Exchange Commission. This\nprospectus is in connection with the resale of up to US$60 million of its\ncommon shares which may be issued under the equity line of credit facility, as\nwell as the resale of such senior convertible notes and of the common shares\nissuable upon conversion thereof. An aggregate amount not exceeding\nUS$102.085 million of securities is being registered under the shelf\nprospectus and registration statement.\n\n\nNeurochem has not been advised by any holder of notes of an intention to\nsell the notes or any common shares under the prospectus. In the event that\nnotes or common shares are to be sold under the shelf prospectus, Neurochem\nwill prepare and file a prospectus supplement that will include the specific\nterms of the designated securities.\n\n\nWhen available, copies of the base prospectus and applicable prospectus\nsupplement may be obtained from Neurochem Inc., Corporate Secretary,\n275 Armand-Frappier Boulevard, Laval, Quebec, H7V 4A7, or from any underwriter\nor dealer participating in the offering.\n\n\nA registration statement relating to these securities has been filed with\nthe U.S. Securities and Exchange Commission, but has not yet become effective.\nThese securities may not be sold, nor may offers to buy be accepted, prior to\nthe time the registration statement becomes effective. This announcement is\nneither an offer to sell nor a solicitation of an offer to buy any of these\nsecurities and shall not constitute an offer, solicitation or sale in any\njurisdiction in which such offer, solicitation or sale is unlawful.\n\n\nAbout Neurochem\n\n\nNeurochem Inc. is focused on the development and commercialization of\ninnovative therapeutics to address critical unmet medical needs. Eprodisate\n(KIACTA(TM); formerly FIBRILLEX(TM)) is currently being developed for the\ntre...